- Projects & figures
- News & Events
- Managing your project
- About ERC
A targeted and personalised method for triggering the body’s immune response could transform how we treat cancer. Thanks to a grant from the European Research Council (ERC), an inspired idea has been developed in the lab and turned into a ground-breaking commercial opportunity.
New families of proteins and enzymes will enable the development of novel plant-based biomaterials, potentially providing viable sustainable and renewable alternatives to plastics and other fossil-fuel-derived materials and chemicals.
Based on University of Turku's press release
For more than 3000 years, men have captured wild Asian elephants to use them for work or entertainment. In a new study published today in Nature Communications, ERC grantee Virpi Lummaa shows the harmful effects of these ongoing practices on wild-caught animals. The findings are based on detailed records from the past 100 years over a population of 5000 timber elephants from Myanmar.
The use and misuse of antibiotics has accelerated the emergence of drug-resistant bacterial strains, threatening our ability to treat common diseases. EU-funded research has shed new light on the mechanisms behind these microbial mutations, with implications for our understanding of diseases and resistance to treatment.
Virpi Lummaa holds an Academy of Finland Professorship at the University of Turku, Finland. She is interested in ageing, lifespan and natural selection in contemporary human populations, looking at evolutionary, ecological and demographic factors. At present, Prof. Lummaa also focuses on senescence patterns of the Asian elephant, a long-lived mammal that offers unique opportunities to address ageing mechanisms. Her latest findings highlight the significant role that elephant grandmothers play to ensure the survival of the calves, providing vital baby elephant care comparable to childcare in human communities across the world. Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."
Maria Brandão de Vasconcelos, together with her colleague Filipa Matos Baptista, Henrique Veiga-Fernandes (ERC grantee), Diogo Fonseca Pereira and Sílvia Arroz Madeira, founded StemCell2MAX in 2015. The company is a biotechnology start-up, specialised in cell based therapies, including novel solutions to multiply the scarcely available blood stem cells, addressing an enormous demand for research and cancer treatment. StemCell2MAX technology is based on Prof. Veiga-Fernandes's ground-breaking discoveries in hematopoietic stem cell biology.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."
Haematopoietic Stem Cells (HSCs) are blood cells located in the bone marrow. These cells are extensively used in research to develop treatments for many severe diseases, including HIV and multiple sclerosis, and their transplant is a key therapy for certain types of cancer like leukemia and multiple myeloma. However, the use of HSCs is seriously constrained by their limited availability since growing them in the lab does not produce very large quantities. There is therefore an urgent need for methods allowing scientists to multiply HSCs, without losing any of their properties.
Why do so many diabetes patients develop kidney disease, and how can we improve prevention? EU-funded research has examined insulin-related processes at play in impaired renal function — and it may have found a way to protect key cells that help to filter our blood.
ERC grantee Marta Moita and her team use cutting-edge experimental procedures to investigate how rats and flies learn to appropriately respond to danger from other individuals. The results of her study may teach us a lot about our own brains, and shed light on diseases that impair social behaviour.
Solar power is potentially an almost limitless resource. The sun provides enough energy in one minute to supply the world’s energy needs for one year. But turning this resource into affordable electricity is difficult – silicon-based solar cells still suffer from a decline in their effectiveness over time. Through her ERC-funded SOLARX project, Professor Hele Savin, of Aalto University in Finland, is investigating a possible route to solving this problem.